WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Katina Dorton, J.D., M.B.A., to its Board of Directors. Ms. Dorton brings more than 25 years of experience in the biopharma industry and finance to TScan.

“Katina is a global financial executive with over 25 years of diverse experience as Chief Financial Officer at several leading biotechnology companies and as a trusted strategic advisor to emerging life science companies through her career in investment banking,” said David Southwell, Chief Executive Officer and President at TScan. “We welcome Katina to our Board of Directors and look forward to her contributions as we continue to grow our organization and work to advance our pipeline of novel TCR-T therapies for liquid and solid tumors.”

“It is a privilege to be joining TScan’s Board of Directors, especially during a period of high growth as the Company readies for its transition to the clinical-stage with the advancement of its TCR-T therapy candidate portfolio,” said Ms. Dorton. “I believe TScan is well positioned to become a leader in the development of TCRT therapies due to its proprietary technology platform for target discovery, emerging pipeline of product candidates with both validated and novel targets and experienced management team.”

Ms. Dorton currently serves as Chief Financial Officer of Nodthera Limited, a company developing medicines to inhibit the NLRP3 inflammasome. She also serves on the board of directors for Fulcrum Therapeutics, Inc., Pandion Therapeutics, Inc., and US Ecology, Inc. Previously Ms. Dorton has held Chief Financial Officer positions at several biotechnology companies, including Repare Therapeutics Inc., a synthetic lethality and DNA repair-focused oncology company, AVROBIO, Inc., a lentiviral gene therapy company from and Immatics GmbH. Earlier in her career, Ms. Dorton served as a Managing Director in investment banking for Morgan Stanley and Needham & Company and as an attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from Duke University.

About TScan Therapeutics

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiple TCR-T therapy candidates for the treatment of various solid tumors. For more information, visit https://www.tscan.com.

Media Contact:

David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com

Investor Contact:

Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com